3D MEDICINES(01244.HK)由紀錄高回吐11% 受配股消息拖累
早前發盈喜料中期毛利大增逾66%推動股價屢創上市新高的3D MEDICINES(01244.HK)擬趁高「抽水」,今早股價平開後,曾續升至127元(受制昨天盤中所創上市高位131.5元),掉頭輾轉滑落,最低見110.4元,現報110.6元,回吐11%,結束六連升,成交額3,793萬元。
3D MEDICINES公布,擬透過配售代理以每股108元(較昨天收市價折讓近13%),向不少於六名獨立承配人配售215萬股,料淨籌約2.26億元,主要用於為評估恩沃利單抗單一療法而計劃進行的臨床試驗,以及用作建設中國徐州生產設施和為其採購設備等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.